A new patent to push treatments further
With its new CELLU M6 Alliance technology, LPG has created an even more accurate, more personalised, brand new treatment to target connective tissue malfunctions while respecting the skin. Thanks to a new Alliance Skin Identity (ASI) sensor, the practitioner can adapt their work to suit the patient’s tissue quality.
They can accurately control how they increase the patient’s vascularisation, taking into account the patient’s cicatricial condition while acting directly upon the inflammatory tissue. This tenth generation Cellu M6 required more than a year of R&D to integrate twenty-two highly relevant new treatment protocols for senology, orthopaedics, angiology, burn therapy, urogynecology and obesity.
To locate your nearest LPG centre: www.lpgmedical.com/en/
